Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRK-950 in Combination With Selected Anti-Cancer Treatment Regimens in Advanced Solid Tumors
NCT03872947Phase 1Completed
- Sponsor
- Toray Industries
- Start
- Apr 2019
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of TRK-950 in solid tumor, colorectal cancer (CRC), cholangiocarcinoma (CCA) and 7 more (15 arms), sponsored by Toray Industries. Primary endpoints: Frequency of patients experiencing treatment emergent adverse events, Frequency of patients experiencing adverse events of special interest and 10 more. Started Apr 2019; status: completed.
02
Drugs
TRK-950
03
Conditions
solid tumorcolorectal cancer (CRC)cholangiocarcinoma (CCA)bladder cancerovarian cancer
Beyond the preview
Go deeper on NCT03872947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872947.